HeartBeam (BEAT) stock price is $0.41, down 0.53% on the day, as of Oct 20, 2026. It has a market cap of $21.46Mn, and is classified in the Medical Devices industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap21.46 Mn
P/E-1.06
P/S195.12
Div. Yield0.00
Revenue Growth (1y) (Qtr)-15.87
Add ratio to table…
About
HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. The company develops higher resolution ambulatory cardiac monitoring solutions that enable detection and monitoring of cardiac disease outside healthcare facilities. Its core innovation lies in a proprietary patented technology platform that collects the heart’s electrical activity from three dimensions and synthesizes a 12-Lead ECG from these signals.…
HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. The company develops higher resolution ambulatory cardiac monitoring solutions that enable detection and monitoring of cardiac disease outside healthcare facilities. Its core innovation lies in a proprietary patented technology platform that collects the heart’s electrical activity from three dimensions and synthesizes a 12-Lead ECG from these signals. HeartBeam’s initial product and service offering is the HeartBeam System, which is the first U. S. FDA cleared cable-free ambulatory 12L ECG that captures cardiac signals in three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment. The system includes a credit card sized 3D ECG recording device, a patient application, a physician portal, and cloud-based algorithms.
HeartBeam generates revenue through the sale of its HeartBeam System and associated services. The primary product is the FDA cleared cable-free ambulatory 12L ECG device designed for arrhythmia assessment. Revenue is derived from the sale of the hardware device, patient application access, physician portal usage, and cloud-based algorithm services. The company targets customers seeking convenient cardiac monitoring solutions outside traditional healthcare settings. As of December 31, 2025, HeartBeam had not generated any revenue from the HeartBeam System, as it was focused on post-clearance commercialization activities following FDA clearance in December 2024 for arrhythmia assessment and December 2025 for the 12-Lead ECG synthesis software.
The company operates through the following segments:
HeartBeam System segment. This segment encompasses the development, manufacturing, and commercialization of the HeartBeam System, which includes the credit card sized 3D ECG recording device, patient application, physician portal, and cloud-based algorithms for synthesizing a 12-Lead ECG from three-dimensional cardiac signals. The segment focuses on arrhythmia assessment and is supported by FDA clearances obtained in December 2024 and December 2025. Activities include limited market launch in early 2026 targeting concierge and preventive cardiology groups, pursuit of heart attack detection indication, development of an extended wear patch monitor, and longitudinal data and AI initiatives for future screening and prediction algorithms.
HeartBeam operates in a competitive cardiac monitoring and detection market characterized by rapid technological change. The company faces competition from consumer devices such as Apple Watch, AliveCor’s KardiaMobile, Google Pixel 2, and Samsung Galaxy Watch, which are single-lead ECG devices primarily intended for arrhythmia detection and not ischemia detection. In the prescribed devices for ischemia detection segment, competitors include Avertix Medical’s AngelMed Guardian implantable cardiac monitor and SHL Telemedicine’s Smartheart home-based 12L ECG system. Patch monitoring companies such as iRhythm Technologies, Boston Scientific’s BodyGuardian, and BioTelemetry (a Philips subsidiary) offer single or 3-lead ECG patches limited to arrhythmia detection. HeartBeam differentiates itself through its patented cable-free technology that captures cardiac signals in three non-coplanar dimensions and synthesizes them into a 12-Lead ECG display, offering a portable, easy-to-use solution that provides comprehensive diagnostic data comparable to standard 12L ECG machines. Its competitive advantages include the credit card sized form factor, personalized baseline ECG capability, and integration with on-demand cardiologist review.
HeartBeam serves customers in the cardiac monitoring market, including patients, healthcare providers, and healthcare payers. The company’s primary customers are concierge physicians, preventive cardiology practices, and cardiology departments of hospitals. Healthcare insurers are also an important customer segment due to potential cost savings to the healthcare system. The company targets market segments that value an easy-to-use medical-grade ECG device, including concierge practices, hospital-at-home programs, and clinical trial settings. HeartBeam aims to establish its products as key solutions for these customers through clinical evidence, cost-effectiveness demonstrations, and reference site development.
Sector:HealthcareSector rationaleHeartBeam develops and sells the HeartBeam System, an FDA-cleared medical device for ambulatory 12-lead ECG recording and arrhythmia assessment. Its primary customers are healthcare providers, such as cardiology practices and hospitals, and its revenue model is based on the sale of medical hardware and associated diagnostic services.Industries:Medical DevicesMedical DevicesPrimaryHeartBeam designs and manufactures the HeartBeam System, which is an FDA-cleared cable-free ambulatory 12L ECG recording device used for arrhythmia assessment. This is a therapeutic and surgical medical device used for clinical diagnostics outside of healthcare facilities.Diagnostic EquipmentDiagnostic EquipmentSecondaryThe company sells cloud-based algorithms and a physician portal used to synthesize 12-Lead ECGs from 3D signals for advanced diagnostics. These software components and the associated hardware function as a clinical diagnostic platform for arrhythmia and ischemia detection.Classified using BQ-MICSCIK: 0001779372
Bull & bear
Investment Thesis
▲ Bull case
HeartBeam's 3D ECG technology platform creates a unique defensible moat that extends beyond its initial cleared indication for arrhythmia assessment, as the core signal collection technology can be applied to multiple form factors without requiring new regulatory clearance for each application, enabling rapid expansion into high-value markets like heart attack detection and ischemia monitoring using the same proprietary IP. This structural advantage allows the company to leverage its existing FDA clearances as a foundation for future indications, significantly reducing regulatory risk and time-to-market for new products such as the on-demand 12-lead patch and AI-driven MI detection algorithms, which are critical for capturing the $2 billion ambulatory cardiac monitoring market and the $40 billion total addressable market referenced by management. The ability to repurpose the same hardware and software core across episodic (card), continuous (patch), and analytical (AI) use cases creates a flywheel effect where adoption in one segment drives demand in others, particularly as physicians transition patients from patch-based monitoring to long-term card use after acute events, thereby increasing lifetime value per patient and reinforcing sticky physician relationships in flagship accounts.
The limited commercial launch strategy, focused on deep adoption within a select group of high-value concierge and preventive cardiology practices in four key geographies, is de-risking commercial execution by validating workflow integration and pricing acceptance with early adopters who are less price-sensitive and more likely to champion the technology, as evidenced by the absence of pushback on the $750 to $1,000 annual subscription fee and the expansion of ClearCardio into New York and South Florida alongside Atelier Health in Southern California. This approach allows HeartBeam to refine its commercial playbook with a lean team (currently one sales director and one implementation specialist) while building clinical proof points and physician testimonials that will lower the cost of customer acquisition and accelerate scalability when expanding to broader markets in 2027, particularly since the company estimates its breakeven point requires converting just 30,000 of the 150,000 patients in the preventative concierge market—a target that appears achievable given the flagship account traction and structured onboarding process being developed with partners like ClearCardio and Atelier.
Progress in heart attack detection and AI initiatives, particularly the ALIGN ACS pilot study enrolling ahead of schedule and the strategic collaboration with Mount Sinai, represents a hidden catalyst that management underemphasized during the call, as the focus on ischemia detection in the patch study and regulatory timelines obscured the broader implication that successful AI algorithm development could enable the HeartBeam system to detect both STEMI and NSTEMI events with higher accuracy than physician interpretation alone, directly addressing the critical unmet need where 30–40% of heart attacks are initially missed in emergency settings. By training deep learning models on outcomes-based data (e.g., which patients actually received revascularization), the company is positioning its technology not just as a diagnostic tool but as a clinical decision-support system that could become standard of care for chest pain evaluation, thereby expanding the addressable market beyond the 20 million at-risk patients to include routine cardiac wellness screening and personalized risk assessment—opportunities that could drive recurring revenue streams and significantly enhance the lifetime value of each device sold, especially as reimbursement pathways for AI-assisted ECG interpretation continue to evolve in favor of software-based diagnostic aids.
The recent $11.5 million financing, led by strategic participation from first commercial customer ClearCardio alongside fundamental institutional investors, provides more than just cash runway—it signals strong validation of the business model from parties with deep operational and financial insight into HeartBeam’s commercial traction, reducing perceived financing risk and enabling the company to maintain its capital-efficient strategy without forced dilution or disruptive fundraising timelines, which is critical given the updated cash outflow guidance of below $16 million for all of 2026 (down from the prior $17–19 million range) and the pro forma cash balance of ~$12.4 million post-offering. This financial flexibility allows HeartBeam to continue advancing multiple growth initiatives in parallel—the limited commercial launch, the 12-lead patch pilot study, the ALIGN ACS study, and AI algorithm development—without having to prioritize one over another due to cash constraints, thereby increasing the probability of hitting key inflection points in 2026 such as pivotal study design completion for heart attack detection or partnership finalization for the patch, both of which could serve as near-term valuation catalysts.
HeartBeam's 3D ECG technology platform creates a unique defensible moat that extends beyond its initial cleared indication for arrhythmia assessment, as the core signal collection technology can be applied to multiple form factors without requiring new regulatory clearance for each application, enabling rapid expansion into high-value markets like heart attack detection and ischemia monitoring using the same proprietary IP. This structural advantage allows the company to leverage its existing FDA clearances as a foundation for future indications, significantly reducing regulatory risk and time-to-market for new products such as the on-demand 12-lead patch and AI-driven MI detection algorithms, which are critical for capturing the $2 billion ambulatory cardiac monitoring market and the $40 billion total addressable market referenced by management. The ability to repurpose the same hardware and software core across episodic (card), continuous (patch), and analytical (AI) use cases creates a flywheel effect where adoption in one segment drives demand in others, particularly as physicians transition patients from patch-based monitoring to long-term card use after acute events, thereby increasing lifetime value per patient and reinforcing sticky physician relationships in flagship accounts.
The limited commercial launch strategy, focused on deep adoption within a select group of high-value concierge and preventive cardiology practices in four key geographies, is de-risking commercial execution by validating workflow integration and pricing acceptance with early adopters who are less price-sensitive and more likely to champion the technology, as evidenced by the absence of pushback on the $750 to $1,000 annual subscription fee and the expansion of ClearCardio into New York and South Florida alongside Atelier Health in Southern California. This approach allows HeartBeam to refine its commercial playbook with a lean team (currently one sales director and one implementation specialist) while building clinical proof points and physician testimonials that will lower the cost of customer acquisition and accelerate scalability when expanding to broader markets in 2027, particularly since the company estimates its breakeven point requires converting just 30,000 of the 150,000 patients in the preventative concierge market—a target that appears achievable given the flagship account traction and structured onboarding process being developed with partners like ClearCardio and Atelier.
Progress in heart attack detection and AI initiatives, particularly the ALIGN ACS pilot study enrolling ahead of schedule and the strategic collaboration with Mount Sinai, represents a hidden catalyst that management underemphasized during the call, as the focus on ischemia detection in the patch study and regulatory timelines obscured the broader implication that successful AI algorithm development could enable the HeartBeam system to detect both STEMI and NSTEMI events with higher accuracy than physician interpretation alone, directly addressing the critical unmet need where 30–40% of heart attacks are initially missed in emergency settings. By training deep learning models on outcomes-based data (e.g., which patients actually received revascularization), the company is positioning its technology not just as a diagnostic tool but as a clinical decision-support system that could become standard of care for chest pain evaluation, thereby expanding the addressable market beyond the 20 million at-risk patients to include routine cardiac wellness screening and personalized risk assessment—opportunities that could drive recurring revenue streams and significantly enhance the lifetime value of each device sold, especially as reimbursement pathways for AI-assisted ECG interpretation continue to evolve in favor of software-based diagnostic aids.
The recent $11.5 million financing, led by strategic participation from first commercial customer ClearCardio alongside fundamental institutional investors, provides more than just cash runway—it signals strong validation of the business model from parties with deep operational and financial insight into HeartBeam’s commercial traction, reducing perceived financing risk and enabling the company to maintain its capital-efficient strategy without forced dilution or disruptive fundraising timelines, which is critical given the updated cash outflow guidance of below $16 million for all of 2026 (down from the prior $17–19 million range) and the pro forma cash balance of ~$12.4 million post-offering. This financial flexibility allows HeartBeam to continue advancing multiple growth initiatives in parallel—the limited commercial launch, the 12-lead patch pilot study, the ALIGN ACS study, and AI algorithm development—without having to prioritize one over another due to cash constraints, thereby increasing the probability of hitting key inflection points in 2026 such as pivotal study design completion for heart attack detection or partnership finalization for the patch, both of which could serve as near-term valuation catalysts.
HeartBeam's reliance on a direct-to-patient, subscription-based model within a narrow segment of concierge and preventive cardiology practices creates significant adoption risk, as the company has not disclosed concrete patient conversion metrics from its flagship accounts despite claiming traction, and the breakeven target of 30,000 patients out of a 150,000-addressable concierge market implies a 20% penetration rate that may be overly optimistic given the lack of pricing transparency beyond a stated $750–$1,000 annual fee and the absence of third-party validation on physician willingness to pay or patient adherence, especially when compared to established cardiac monitoring solutions that benefit from broader insurance reimbursement and physician familiarity. The commercial rollout remains dependent on a lean team (one sales director and one implementation specialist nationally) to drive adoption in privately held practices that are not obligated to share data, making it difficult to validate whether early engagement translates into sustained usage or revenue recognition, and increasing the risk that the current flagship account strategy could stall without broader market pull or demonstrable clinical outcomes impacting reimbursement decisions.
The 12-lead patch initiative, while positioned as a disruptive innovation in the $2 billion ambulatory cardiac monitoring market, faces substantial hurdles in achieving best-in-class status due to its reliance on a two-finger touch mechanism for 12-lead ECG synthesis, which may limit usability during physical activity or in patients with mobility issues—critical flaws in a market where existing patches (e.g., Zio, BioTelemetry) are designed for passive, continuous wear over 14–30 days without user interaction, and the company’s own admission that the patch records only a single lead continuously while depending on manual interaction for the 12-lead synthesis undermines its claim to continuous monitoring parity, especially since ischemia detection requires capturing transient ST-segment changes that may be missed if the patient does not trigger a reading at the precise moment of symptom onset, thereby reducing clinical utility compared to devices that provide uninterrupted data streams.
Progress in heart attack detection and AI, while scientifically promising, is being advanced through studies (ALIGN ACS, Head Start ACS) that enroll patients in emergency departments presenting with chest pain—a design that introduces significant selection bias and limits generalizability to the broader at-risk population, as these patients already have a high pre-test probability of cardiac events, making it easier to demonstrate algorithmic performance without proving utility in lower-prevalence settings such as primary care or wellness screening, and the reliance on Mount Sinai for algorithm development creates execution risk given the lack of disclosed timelines, data sharing agreements, or milestones for the AI model’s validation, regulatory submission, or integration into the HeartBeam system, leaving investors to assume that a complex deep learning solution for detecting subtle NSTEMIs will be ready for pivotal study design within a constrained timeframe despite the historical difficulty of AI in cardiology achieving consistent real-world performance across diverse populations and ECG acquisition conditions.
The company’s financial runway, while strengthened by the $11.5 million offering, remains fragile when scrutinized beyond the headline figures, as the Q1 2026 operating cash burn of $3.6 million (a 19% YoY improvement) still implies an annualized burn rate of ~$14.4 million if sustained, leaving the pro forma $12.4 million cash balance insufficient to cover a full year of operations at current spend levels, and the reliance on upfront customer payments for cash flow—while beneficial in the short term—creates revenue recognition timing mismatches that could mask underlying demand weakness, particularly since the limited commercial launch has not yet disclosed any recurring revenue from existing accounts beyond initial onboarding fees, raising concerns that the current cash position may necessitate another dilutive financing before meaningful scale is achieved, especially if commercial adoption lags or patch development requires unexpected additional investment.
HeartBeam's reliance on a direct-to-patient, subscription-based model within a narrow segment of concierge and preventive cardiology practices creates significant adoption risk, as the company has not disclosed concrete patient conversion metrics from its flagship accounts despite claiming traction, and the breakeven target of 30,000 patients out of a 150,000-addressable concierge market implies a 20% penetration rate that may be overly optimistic given the lack of pricing transparency beyond a stated $750–$1,000 annual fee and the absence of third-party validation on physician willingness to pay or patient adherence, especially when compared to established cardiac monitoring solutions that benefit from broader insurance reimbursement and physician familiarity. The commercial rollout remains dependent on a lean team (one sales director and one implementation specialist nationally) to drive adoption in privately held practices that are not obligated to share data, making it difficult to validate whether early engagement translates into sustained usage or revenue recognition, and increasing the risk that the current flagship account strategy could stall without broader market pull or demonstrable clinical outcomes impacting reimbursement decisions.
The 12-lead patch initiative, while positioned as a disruptive innovation in the $2 billion ambulatory cardiac monitoring market, faces substantial hurdles in achieving best-in-class status due to its reliance on a two-finger touch mechanism for 12-lead ECG synthesis, which may limit usability during physical activity or in patients with mobility issues—critical flaws in a market where existing patches (e.g., Zio, BioTelemetry) are designed for passive, continuous wear over 14–30 days without user interaction, and the company’s own admission that the patch records only a single lead continuously while depending on manual interaction for the 12-lead synthesis undermines its claim to continuous monitoring parity, especially since ischemia detection requires capturing transient ST-segment changes that may be missed if the patient does not trigger a reading at the precise moment of symptom onset, thereby reducing clinical utility compared to devices that provide uninterrupted data streams.
Progress in heart attack detection and AI, while scientifically promising, is being advanced through studies (ALIGN ACS, Head Start ACS) that enroll patients in emergency departments presenting with chest pain—a design that introduces significant selection bias and limits generalizability to the broader at-risk population, as these patients already have a high pre-test probability of cardiac events, making it easier to demonstrate algorithmic performance without proving utility in lower-prevalence settings such as primary care or wellness screening, and the reliance on Mount Sinai for algorithm development creates execution risk given the lack of disclosed timelines, data sharing agreements, or milestones for the AI model’s validation, regulatory submission, or integration into the HeartBeam system, leaving investors to assume that a complex deep learning solution for detecting subtle NSTEMIs will be ready for pivotal study design within a constrained timeframe despite the historical difficulty of AI in cardiology achieving consistent real-world performance across diverse populations and ECG acquisition conditions.
The company’s financial runway, while strengthened by the $11.5 million offering, remains fragile when scrutinized beyond the headline figures, as the Q1 2026 operating cash burn of $3.6 million (a 19% YoY improvement) still implies an annualized burn rate of ~$14.4 million if sustained, leaving the pro forma $12.4 million cash balance insufficient to cover a full year of operations at current spend levels, and the reliance on upfront customer payments for cash flow—while beneficial in the short term—creates revenue recognition timing mismatches that could mask underlying demand weakness, particularly since the limited commercial launch has not yet disclosed any recurring revenue from existing accounts beyond initial onboarding fees, raising concerns that the current cash position may necessitate another dilutive financing before meaningful scale is achieved, especially if commercial adoption lags or patch development requires unexpected additional investment.